Effect of systemic immunosuppression on coronary in-stent intimal hyperplasia in renal transplant patients

Autor:	José Osmar Medina Pestana, Fábio S. Brito, Marco A. Costa, Érika P. Ribeiro, J. Airton Arruda, Valter C. Lima, H. Tedesco, Adriano Henrique Pereira Barbosa
Rok vydání:	2003
Předmět:	Male medicine.medical_specialty Pathology Intimal hyperplasia medicine.medical_treatment Urology Coronary Angiography Endosonography Coronary artery disease Coronary Restenosis Restenosis Internal medicine Azathioprine medicine Humans Immunosuppression Therapy Kidney Hyperplasia business.industry Vascular disease Stent Immunosuppression Middle Aged medicine.disease Coronary Vessels Kidney Transplantation Transplantation surgical procedures operative medicine.anatomical_structure Cardiology Cyclosporine Prednisone Drug Therapy Combination Female Stents Cardiology and Cardiovascular Medicine business Tunica Intima Immunosuppressive Agents Follow-Up Studies
Zdroj:	The American journal of cardiology. 91(11)
ISSN:	0002-9149
Popis:	Cyclosporin, combined with other agents, is an immunosuppressive agent approved for prophylaxis of renal transplant rejection. In experimental studies, cyclosporin has been shown to inhibit smooth muscle cell proliferation in the vascular response to injury. 1,2 Similar experimental results have been observed with systemic use of rapamycin. 3,4 The aim of this clinical investigation was to test the hypothesis that systemic immunosuppression therapy inhibits in-stent restenosis in renal transplant patients with coronary artery disease treated with stenting.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b019eb1c4c33c20a3692a0fdf18a99f4 https://pubmed.ncbi.nlm.nih.gov/12767437 Zobrazit plný text záznamu Full Text from ScienceDirect